Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH
Journal of Medicinal Chemistry · 12.09.2024 · 67 (17) · 14840-14851
DOI: 10.1021/acs.jmedchem.4c01029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.09.2024. Verfasst von Koen Vandyck und 21 weiteren Autor:innen. Beteiligte Einrichtung: Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium. Hauptthemen laut MEDLINE: Thyroid Hormone Receptors beta. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Agonists of thyroid hormone receptor β (THR-β) decreased LDL cholesterol (LDL-C) and triglyceride (TG) levels in human clinical trials for patients with dyslipidemia. The authors present the highly potent and selective compound ALG-055009 (14) as a potential best in class THR-β agonist. The high metabolic stability and good permeability translated well in vivo to afford a long in vivo half-life pharmacokinetic profile with limited liability for DDI, and it overcomes certain drawbacks seen in recent clinical candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium.
- Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States.
- Pharmaron, 6 Taihe Road, BDA, Beijing, 100176, P. R. China.
- Proteros Biostructures GmbH, Bunsenstraße 7a, 82152 Planegg-Martinsried, Germany.
ORCID-Profile: David C McGowan, Antitsa D Stoycheva
Zitieren
APA
Vandyck, K., McGowan, D. C., Luong, X. G., Stevens, S. K., Jekle, A., Gupta, K., Misner, D. L., Chanda, S., Serebryany, V., Welch, M., Hu, H., Lv, Z., Williams, C., Maskos, K., Lammens, A., Stoycheva, A. D., Lin, T. I., Blatt, L. M., Beigelman, L. N., …, & Deval, J. (2024). Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH. Journal of Medicinal Chemistry, 67(17), 14840-14851. https://doi.org/10.1021/acs.jmedchem.4c01029
Vancouver
Vandyck K, McGowan DC, Luong XG, Stevens SK, Jekle A, Gupta K, et al. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH. Journal of Medicinal Chemistry. 2024;67(17):14840-14851. doi:10.1021/acs.jmedchem.4c01029
BibTeX
@article{Vandyck2024,
author = {Vandyck, Koen and McGowan, David C and Luong, Xuan G and Stevens, Sarah K and Jekle, Andreas and Gupta, Kusum and Misner, Dinah L and Chanda, Sushmita and Serebryany, Vladimir and Welch, Michael and Hu, Haiyang and Lv, Zhidan and Williams, Caroline and Maskos, Klaus and Lammens, Alfred and Stoycheva, Antitsa D and Lin, Tse-I and Blatt, Lawrence M and Beigelman, Leonid N and Symons, Julian A and Raboisson, Pierre and Deval, Jerome},
title = {Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {17},
pages = {14840--14851},
doi = {10.1021/acs.jmedchem.4c01029}
}
EUVIMED